This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

ceftaroline fosamil (Zinforo®)

Reference No. 4343

Publication date:

Appraisal information

ceftaroline fosamil (Zinforo®) 600 mg powder for concentrate for solution for infusion

Company: Pfizer Ltd
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 10/02/2020

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, ceftaroline fosamil (Zinforo®) cannot be endorsed for use within NHS Wales for the treatment of the following infections in neonates, infants, children and adolescents: complicated skin and soft tissue infections; community-acquired pneumonia. Additional note: AWMSG has previously accepted ceftaroline fosamil for restricted use in adults with suspected methicillin resistant Staphylococcus aureus (MRSA) skin and soft tissue infection and this advice remains in place.
Statement of Advice (SOA)